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Abbreviations	14 
2-AG:	2-arachidonoyl	glycerol	15 
BMI:	Body	mass	index	16 
CB1:	Cannabinoid	receptor	1	17 
CB2:	Cannabinoid	receptor	2	18 
CRP:	C-reactive	protein	19 
DAGL:	Diacylglycerol	lipase	20 
ECS:	Endocannabinoid	system	21 
FAAH:	Fatty	acid	amide	hydrolase	22 
HDL-C:	High	density	lipoprotein	cholesterol	23 
HOMAIR:	Homeostatic	Model	Assessment	for	Insulin	Resistance	24 
IL-6:	Interleukin-6	25 
LDL-C:	Low	density	lipoprotein	cholesterol	26 
NAPE-PLD:	N-acyl	phosphatidylethanolamine	phospholipase	D	27 
MAGL:	Monoacylglycerol	lipase	28 
MetS:	Metabolic	syndrome	29 
SNP:	Single	nucleotide	polymorphism	30 
TGs:	Triglycerides	31 
TNFα:	Tumour	necrosis	factor	alpha	32 
T2DM:	Type	2	Diabetes	Mellitus	33 
WC:	Waist	circumference	34 
WHR:	Waist-to-hip	ratio35 
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Abstract	36 
The	endocannabinoid	system	(ECS)	is	involved	in	many	physiological	processes	including	fertility,	37 
pain	and	energy	regulation.	The	aim	of	this	systematic	review	was	to	examine	the	contribution	of	38 
single	nucleotide	polymorphisms	(SNPs)	of	the	ECS	to	adiposity	and	glucose	metabolism.	39 
Database	searches	returned	734	articles,	of	which	65	were	included	covering	70	SNPs	in	genes	40 
coding	for	cannabinoid	receptors	1	and	2	(CB1,	CB2),	fatty	acid	amide	hydrolase	(FAAH)	and	N-41 
acyl	phosphatidylethanolamine	phospholipase	D	(NAPE-PLD).	No	studies	included	SNPs	relating	42 
to	monoacylglycerol	lipase	or	diacylglycerol	lipase.	The	CB1	receptor	SNP	rs1049353	showed	17	43 
associations	with	lower	body	mass	index	(BMI)	and	fat	mass	(5	studies).	It	also	showed	3	44 
associations	with	lower	insulin	levels	(1	study).	Conversely,	the	CB1	receptor	SNP	rs806368	was	45 
associated	with	increased	BMI	and	waist	circumference	(2	studies).	The	FAAH	SNP	rs324420	as	46 
associated	with	increased	obesity	(3	studies).	A	haplotype	of	NAPE-PLD	was	associated	with	47 
decreased	BMI	(1	study).	60	SNPs	showed	no	association	with	any	measured	outcome.	This	48 
review	suggests	a	complex	but	important	role	of	ECS	SNPs	in	energy	and	glucose	metabolism.	49 
50 
 
 
Introduction	51 
The	endocannabinoid	system	(ECS)	consists	of	two	G-protein	coupled	receptors	(CB1	and	CB2)	52 
and	endogenously	produced	ligands	(or	endocannabinoids,	such	as	anandamide	and	2-53 
arachidonoyl	glycerol)	and	the	enzymes	involved	in	their	synthesis	or	degradation;	fatty	acid	54 
amide	hydrolase	(FAAH),	monoacylglycerol	lipase	(MAGL),	diacylglycerol	lipase	(DAGL)	and	N-acyl	55 
phosphatidylethanolamine	phospholipase	D	(NAPE-PLD).	It	is	well	established	that	CB1	activation	56 
leads	to	increases	in	energy	storage	1	which	occurs	via	increased	motivation	to	consume	food	57 
and	decreased	satiety.		58 
	59 
Single	nucleotide	polymorphisms	(SNPs)	are	naturally	occurring	variations	of	a	genetic	sequence,	60 
which	often	affect	protein	structure.	To	date,	studies	on	the	effects	of	endocannabinoid	SNPs	61 
have	focused	on	central	disorders	such	as	Parkinson’s	disease	and	Alzheimer’s	disease	2.	62 
However,	there	is	accumulating	evidence	for	the	role	of	endocannabinoid	SNPs	in	adiposity	3	and	63 
glucose	metabolism	4.	Therefore,	the	aim	of	this	systematic	review	was	to	systematically	collate	64 
the	evidence	relating	to	SNPs	of	the	ECS	in	obese	or	diabetic	phenotypes.	By	studying	amino	acid	65 
sequence	alterations	and	any	resultant	residue	changes,	we	hoped	to	identify	important	genetic	66 
changes	which	alter	the	normal	physiology	of	adiposity	and	glucose	metabolism.		67 
68 
69 
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Materials	and	Methods	70 
Searches	were	performed	using	PubMed,	EMBASE	and	Web	of	Science	by	two	independent	71 
researchers	and	concluded	on	26/1/2018.	Additional	studies	were	identified	from	bibliographies.	72 
The	search	terms	used	were:	Cannabinoid	OR	endocannabinoid	receptor	OR	CB1	OR	CB2	OR	FAAH	73 
OR	fatty	acid	amide	hydrolase	AND	polymorphism	AND	obesity	OR	diabetes	OR	BMI	OR	74 
monoacylglycerol	lipase	OR	MAGL	OR	diacylglycerol	lipase	OR	DAGL	OR	N-acyl	75 
phosphatidylethanolamine-specific	phospholipase	D	OR	NAPE	PLD.	A	summary	of	search	results	76 
and	exclusions	is	given	in	supplemental	Figure	S1,	and	a	full	reference	list	is	available	in	the	77 
supplementary	appendix.	The	SNP	database	dbSNP	was	used	to	gather	information	regarding	78 
nucleotide	and	amino	acid	changes	5.	79 
	80 
Articles	included	were	original	studies	relating	to	polymorphisms	of	the	ECS	affecting	energy	81 
regulation,	glucose	homeostasis	and	adiposity.	Demographic	and	clinical	parameters	included	82 
were:	body	mass	index	(BMI);	waist	circumference	(WC);	waist-to-hip	ratio	(WHR);	body	weight;	83 
adiposity;	Type	II	Diabetes	Mellitus	(T2DM);	insulin	and	glucose	levels;	Homeostatic	Model	84 
Assessment	for	Insulin	Resistance	(HOMAIR);	adipokine	levels	(adiponectin,	leptin,	and	resistin);	85 
cardiovascular	parameters	(blood	pressure,	heart	rate);	inflammation	(levels	of	interleukin	6	(IL-86 
6),	tumour	necrosis	factor	alpha	(TNFα)	and	C-reactive	protein	(CRP));	and	lipid	levels	87 
(triglycerides,	HDL-C	and	LDL-C).	Records	excluded	were	review	articles,	articles	on	the	ECS	not	88 
relating	to	polymorphisms,	studies	regarding	central	disorders,	non-human	studies	and	studies	in	89 
a	language	other	than	English.		90 
	91 
Included	articles	were	analysed	for	significant	(p<0.05)	positive	or	negative	associations	between	92 
SNPs	and	relevant	parameters.	A	‘positive’	association	refers	to	there	being	a	higher	value	of	the	93 
measured	outcome	in	the	presence	of	the	polymorphism,	whereas	‘negative’	refers	to	there	94 
being	a	lower	value	in	the	presence	of	the	polymorphism.	A	lack	of	significant	association	95 
 
 
between	the	measured	outcome	and	the	polymorphism	is	described	as	a	‘neutral’	association.	96 
Risk	of	bias	was	assessed	using	the	Cochrane	Collaboration’s	tool	for	assessing	risk	of	bias	6.	97 
98 
99 
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Results	100 
65	studies	were	identified	from	733	full-text	articles.	Risk	of	bias	of	these	studies	was	overall	low	101 
and	is	summarised	in	supplemental	Figure	S2.	In	total,	38	CB1,	18	CB2,	13	FAAH	and	1	NAPE-PLD	102 
SNPs	were	studied.	No	studies	relating	to	MAGL	or	DAGL	SNPs	were	found.	The	most	commonly	103 
studied	SNPs	and	those	which	showed	the	most	significant	associations	were	CB1	SNPs	104 
rs1049353	and	rs806368,	and	FAAH	SNP	rs324420.	Their	associations	with	body	weight	and	105 
glucose	metabolism	parameters	are	presented	in	Table	1.	All	SNPs	and	their	associations	with	106 
measured	outcomes	are	documented	in	supplementary	Table	S1.	A	summary	of	all	included	107 
studies	and	their	relevant	findings	is	shown	in	supplementary	Table	S2.	108 
	109 
BMI	and	body	weight		110 
CB1	111 
The	rs1049353	mutant	allele	was	associated	with	lower	BMI	in	six	European	populations	112 
7,8,9,10,11,12	and	decreased	fat	mass	in	a	Danish	population	(n=783)	13.		Conversely,	homozygosity	113 
for	the	rs1049353	mutant	allele	was	associated	with	higher	WHR	and	WC	in	obese	men	(p<0.01,	114 
n=1,064)	14,	and	increased	childhood	obesity	in	a	European	population	(p=0.01,	n=200)	15.	The	115 
majority	of	associations	with	rs1049353	were	neutral	(90%)	(Table	1).	However,	negative	116 
associations	were	more	common	than	positive	(Figure	1),	suggesting	this	SNP	plays	a	part	in	a	117 
more	complex	genetic	susceptibility	to	increase	adiposity.	Male	carriers	of	the	rs806368	mutant	118 
allele	showed	greater	BMI	values	in	a	Japanese	cohort	(p=0.001),	and	were	more	likely	to	be	119 
obese	(p=0.01,	n=1,452)	16	(Table	S1).	120 
	121 
FAAH	122 
FAAH	polymorphism	rs324420	was	positively	associated	with	obesity	in	four	cohorts	(n=18,987)	123 
17,18,19,20.	124 
	125 
 
 
CB2		126 
The	mutant	allele	of	CB2	SNP	rs3123554	was	associated	with	lower	total	body	fat	in	females	but	127 
not	males	in	a	European	cohort	(p=0.001),	with	lower	BMI	in	subjects	at	risk	of	T2DM	(p<0.01)	128 
and	reduced	weight	loss	(p<0.01,	n=2,006)	21.	129 
	130 
NAPE-PLD	131 
In	a	Norwegian	cohort,	a	haplotype	of	NAPE-PLD	showed	an	association	with	increased	BMI	132 
(p<0.05,	n=5,011)	22.	133 
	134 
Type	II	Diabetes	135 
CB1	136 
The	mutant	allele	of	CB1	polymorphism	rs1049353	was	associated	with	lower	insulin,	glucose	and	137 
HOMAIR	levels	in	Spanish	obese	women	29	and	lower	insulin	in	two	other	European	cohorts	138 
(n=983)	23,24.	CB1	SNP	rs806365	was	associated	with	decreased	HOMAIR	values	and	incidence	of	139 
T2DM	in	a	North	American	cohort	(p=<0.05,	n=2,411)	25.	140 
	141 
CB2	142 
The	mutant	allele	of	CB2	polymorphism	rs3123554	was	associated	with	raised	insulin	levels	and	143 
HOMAIR	values	in	an	obese	population	(n=1,027)	26	(Figure	1).	144 
	145 
FAAH	146 
The	mutant	allele	of	FAAH	polymorphism	rs324420	was	associated	with	lower	insulin	levels	in	147 
two	obese	populations	(p<0.05,	n=165)	27,	28.	rs324420	was	also	associated	with	lower	HOMAIR	148 
levels	in	obese	Spanish	females	(p<0.05,	n=143)	28.	149 
	150 
Lipids	151 
 
 
Overall,	22	positive	associations	with	lipid	levels	were	seen.	The	mutant	allele	of	CB1	SNP	152 
rs1049353	was	associated	with	higher	HDL	and	lower	TGs	in	three	cohorts	29,30,31,	as	well	as	lower	153 
TGs	in	two	populations	(n=808)	9,	29	(Table	1).		154 
	155 
FAAH	SNPs	rs324420	and	rs3123554	were	associated	with	higher	TG	levels	in	European	cohorts	156 
(p<0.05,	n=1,644)	26,	30	(Table	1).	FAAH	SNP	rs324420	was	also	associated	with	raised	anandamide	157 
levels	in	a	Brazilian	population	(p<0.05,	n=200).	42158 
159 
160 
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Discussion	161 
The	aim	of	this	study	was	to	collate	evidence	relating	to	SNPs	of	the	ECS	and	obese	or	diabetic	162 
phenotypes	to	identify	important	genetic	changes	which	alter	metabolism.		From	the	65	included	163 
articles,	70	polymorphisms	were	studied.	CB1	SNP	rs1049353	showed	17	associations	with	lower	164 
BMI	and	fat	mass.	It	also	showed	associations	with	reduced	glucose,	insulin	and	HOMAIR	values.	165 
CB1	polymorphism	rs806368	showed	5	associations	with	increases	in	BMI,	WC	and	WHR.	The	166 
FAAH	SNP	rs324420	showed	7	associations	with	increased	incidence	of	obesity.	60	SNPs	showed	167 
no	association	with	any	measured	outcome.	These	findings	suggest	an	important	role	of	selected	168 
SNPs	of	the	ECS	in	adiposity,	although	the	number	of	studies	showing	no	associations	means	that	169 
their	contribution	is	likely	part	of	complex	interactions.	170 
	171 
The	SNP	rs1049353	occurs	at	nucleotide	position	1359,	a	region	of	the	CB1	(CNR1)	gene	coding	172 
for	the	receptor’s	intracellular	domain	or	C-terminal.	One	study	showed	that	replacement	of	the	173 
C-terminal	resulted	in	decreased	affinity	of	the	CB1	agonist	CP55940	and	increased	affinity	of	the	174 
CB1	antagonist	SR141716A	33.	This	suggests	that	the	C-terminal	is	important	in	receptor	175 
signalling.	Although	rs1049353	is	a	synonymous	SNP	and	does	not	result	in	an	amino	acid	residue	176 
change	(Thr>Thr),	altered	substrate	interaction	deriving	from	synonymous	SNPs	has	been	177 
observed	elsewhere	34	suggesting	this	is	a	legitimate	theory.		178 
	179 
The	literature	showed	13	associations	between	rs1049353	and	reductions	in	parameters	of	180 
glucose	metabolism	9,10,12,14,22,23,24,29,30,39,45,46,48	(Figure	1).	This	suggests	that	that	this	SNP	is	important	181 
in	diabetic	phenotypes,	likely	caused	by	upregulation	of	gluconeogenic	transcription	factors	due	182 
to	increased	CB1	receptor	activity.	It	is	unclear	why	many	studies	(n=14)	showed	no	association	183 
with	parameters	of	glucose	metabolism.	184 
	185 
 
 
The	rs324420	SNP	reduces	FAAH	activity	and	increases	likelihood	for	the	enzyme	itself	to	be	186 
degraded	41,	leading	to	cannabinoid	overactivity.	Subsequent	CB1	activation	leads	to	adipogenesis	187 
and	reduced	expenditure,	all	of	which	contribute	to	obesity-related	phenotypes.		Our	analysis	188 
showed	that	rs324420	was	associated	with	higher	anandamide	levels	42,	increased	BMI	and	189 
obesity	17,18,32,	which	suggests	cannabinoid	over-activation	and	subsequent	adiposity	and	that	190 
this	SNP	therefore	reduces	FAAH	activity	(Table	1).		191 
	192 
The	potential	contribution	of	CNR2	polymorphisms	to	human	metabolism	is	less	clear.	Fewer	193 
studies	investigated	these	SNPs,	and	the	two	polymorphisms	studied	(rs3123554	and	194 
rs35761398)	showed	conflicting	associations	with	body	weight	parameters	and	glucose	195 
metabolism.	As	CB2	receptors	are	found	primarily	in	the	central	nervous	system	and	on	immune	196 
cells,	it	is	likely	that	they	are	less	involved	in	the	regulation	of	body	fat	and	therefore	any	197 
alterations	in	their	genetic	structure	are	less	relevant	here.	As	no	studies	were	found	relating	to	198 
SNPs	of	DAGL	or	MAGL,	their	contribution	to	obesity	and	glucose	metabolism	remains	unclear.	199 
	200 
Increasing	age	may	determine	the	impact	of	the	polymorphism.	For	instance,	associations	201 
between	SNPs	rs2023239	and	rs806381	and	increased	anthropometric	measurements	were	202 
found	only	in	adult	subjects	35,36.	Ageing	leads	to	reductions	in	ligand	binding	37	and	coupling	203 
between	the	CB1	receptor	and	its	G-protein	38,	which	may	account	for	the	delayed	onset	of	204 
increases	in	body	weight	parameters	in	some	populations.	There	may	also	be	an	impact	of	205 
gender	in	these	data.		Male	carriers	of	the	mutant	alleles	of	CNR1	polymorphisms	rs1049353	and	206 
rs806368	have	an	increased	likelihood	of	obesity	14,16.	Similarly,	the	associations	between	the	207 
CNR2	polymorphism	rs3123554	and	lower	BMI,	weight	and	body	fat	percentage	were	reported	in	208 
female	subjects	21.	Gender	differences	in	feeding	behaviour	have	been	previously	observed	in	209 
animal	models	39.	This	may	be	explained	by	the	action	of	oestrogen,	which	uncouples	CB	210 
receptors	from	their	effector	systems	in	synaptic	terminals,	reducing	the	effect	of	cannabinoids	211 
 
 
40.	Higher	oestrogen	levels	in	non-pregnant	females	may	therefore	contribute	to	these	gender-212 
specific	findings.	213 
	214 
In	conclusion,	associations	between	the	mutant	allele	of	the	CB1	SNP	rs1049353	and	decreased	215 
fat	mass,	weight	and	BMI	indicate	that	this	SNP	is	an	important	contributor	to	alterations	in	216 
metabolism.	Evidence	points	to	decreased	receptor	functionality	affecting	normal	pathways	of	217 
adipogenesis	and	energy	regulation.	Its	effects	also	extend	to	improvements	in	lipid	levels	and	218 
parameters	of	glucose	metabolism.	The	mutant	allele	of	FAAH	polymorphism	rs324420	was	219 
associated	with	increased	BMI	and	triglyceride	levels,	possibly	caused	by	decreased	enzyme	220 
activity	and	overactivation	of	the	ECS.	Other	SNPs	had	varying	associations	but	often	presented	221 
conflicting	results.	These	findings	represent	therapeutic	targets	for	the	management	of	obesity	222 
and	hyperlipidaemia,	and	assessment	of	patients	for	these	genetic	changes	would	provide	an	223 
opportunity	to	give	personalised	treatment	for	a	proportion	of	patients.	Further	studies	in	224 
populations	of	varying	demographics	are	needed	to	investigate	the	role	that	other	SNPs	play	in	225 
adiposity	and	glucose	metabolism,	as	well	as	genetic	studies	to	determine	the	molecular	changes	226 
of	SNPs	responsible	for	alterations	in	function.	227 
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Abbreviations:	CNR1,	cannabinoid	receptor	gene	1;	FAAH,	fatty	acid	amide	hydrolase;	WC,	waist	circumference;	WHR,	waist-to-hip	ratio;	BMI,	body	mass	index;	TGs,	triglycerides;	HOMAIR,	homeostatic	model	
assessment	of	insulin	resistance;	TNF-α,	tumour	necrosis	factor	α;	MetS,	metabolic	syndrome;	T2DM,	Type	2	Diabetes	Mellitus.	
	
	
Table	1.	Associations	found	between	single	nucleotide	polymorphisms	and	metabolic	and	anthropometric	parameters.	
Polymorphism	 Gene	 Nucleotide	change	
Nucleotide	
position	
Region	of	
gene	
Amino	acid	
change	
Amino	acid	
position	 Associations	
rs1049353	 CNR1	 G>A	 1359	 Exon	 Thr>Thr	 453	
Positive:	
• Homozygosity	for	mutant	allele	associated	with	increased	WHR	and	WC	in	obese	men	only.14	
• Mutant	allele	associated	with	higher	fat	in	post-menopausal	women.43		
• Mutant	allele	associated	with	increased	BMI	in	T2DM	subjects.44		
• Wild-type	allele	associated	with	higher	HOMAIR.45	
• Mutant	allele	group	associated	with	greater	weight	loss	and	decrease	in	BMI.	46	
• Mutant	allele	associated	with	childhood	obesity.47	
	
Negative:	
• Mutant	allele	associated	with	lower	glucose.46	
• Mutant	allele	associated	with	lower	insulin.	22,39,48	
• Mutant	allele	with	lower	BMI.10,11,12,14,31	
• Mutant	allele	with	lower	HOMAIR,	TGs.9,10,12,14,23,24,29,30	
rs806368	 CNR1	 T>C	 4895	 Intron	 -	 -	
Positive:	
• Mutant	allele	associated	with	increased	WHR.47	
• Mutant	allele	associated	with	increased	TGs.49	
• Mutant	allele	associated	with	increased	BMI,	WC	and	obesity.16	
rs324420	 FAAH	 C>A	 385	 Exon	 Pro>Thr	 129	
Positive:	
• Mutant	allele	associated	with	higher	insulin	and	HOMAIR	in	patients	without	MetS.50	
• Homozygosity	for	mutant	allele	associated	with	increased	BMI.17	
• Mutant	allele	associated	with	obesity.19,20	
• Wild-type	allele	associated	with	childhood	obesity.51		
• Mutant	allele	associated	with	increased	TGs.32	
Negative:	
• Mutant	allele	associated	with	lower	TGs,	glucose	and	HOMAIR	levels.28,44	
• Mutant	allele	associated	with	better	percentage	weight	loss	9	months	and	1	year	after	bariatric	
surgery,	but	not	after	3	months.52	
• Lower	insulin	and	HOMAIR	in	mutant-type	group.	Mutant	allele	associated	with	greater	decreases	
in	weight	and	WC	than	wild-type	following	hypocaloric	diet.	Mutant	allele	also	associated	with	
greater	decreases	in	glucose,	HOMAIR	and	TGs.
27	
• Wild-type	allele	associated	with	lower	WC,	BMI,	HOMAIR	and	TGs	in	subjects	with	MetS.53	
• Mutant	allele	associated	with	lower	insulin,	glucose	and	HOMAIR	values.54	
 
 
 	
	
Figure	1.	Number	of	associations	found	between	ECS	polymorphisms	and	anthropometric	and	diabetic	parameters.	
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Figure	S1:	Summary	of	search	results	and	exclusions 
734 records identified 
through database 
searching 
4 records identified through 
bibliographies/references 
139 records removed due to 
duplication 
599 records after duplicates 
removed 
534 records removed due to 
ineligibility (e.g. review articles, 
central disorders) 
65 full-text articles included 
 
 
	
	
	
Figure	S2:	Results	of	Risk	of	Bias	assessment	for	included	studies 
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Table	S1.	Associations	found	between	single	nucleotide	polymorphisms	and	metabolic	and	anthropometric	parameters.	
Polymorphism	 Gene	 Nucleotide	change	
Nucleotide	
position	
Region	of	
gene	
Amino	acid	
change	
Amino	acid	
position	 Associations	
rs10485170	 CNR1	 A>G	 -	 -	 -	 -	
Neutral:	
• No	association	with	anthropometric	measurements	(weight,	BMI,	WC,	WHR),	biochemical	
measurements	(glucose,	TC,	HDL-C,	LDL-C,	TGs,	insulin,	HOMAir).82	
• No	association	with	anthropometric	measurements	(weight,	BMI,	WC,	total	fat	(g),	fat	(%),	
android	fat	deposit,	biochemical	measurements	(glucose,	TC,	HDL-C,	LDL-C,	TGs,	insulin,	fasting	
insulin	resistance	index)	in	postmenopausal	women.43,91	
• No	association	with	antipsychotic-induced	weight	gain.92	
rs1049353	 CNR1	 G>A	 1359	 Exon	 Thr>Thr	 453	
Positive:	
• Homozygosity	for	mutant	allele	associated	with	increased	WHR	and	WC	in	obese	men	only.14	
• Mutant	allele	associated	with	higher	android	fat	deposit	and	percentage	of	android	fat	in	post-
menopausal	women.43	
• Mutant	allele	associated	with	increased	BMI	in	T2DM	subjects.74	
• Mutant	allele	associated	with	higher	adiponectin	and	visfatin	levels.	Wild-type	group	had	higher	
HOMAir,	TNFa	and	resistin.66	
• Mutant	allele	associated	with	higher	adiponectin	levels.75	
• After	3	months’	diet,	mutant	allele	group	associated	with	greater	weight	loss,	decrease	in	BMI,	
and	decrease	in	LDL.81	
• Homozygosity	for	mutant	allele	associated	with	increased	cholesterol	levels.80	
• Mutant	allele	associated	with	childhood	obesity.15	
• Mutant	allele	associated	with	higher	HDL-C.29,10	
• Mutant	allele	associated	with	lack	of	decrease	in	leptin	following	hypocaloric	diet.76	
	
Neutral:	
• No	association	with	BMI.16,35,64,69	
• No	association	with	BMI,	weight,	WC,	WHR,	glucose,	total	cholesterol,	LDL,	HDL,	TG,	IL-6,	or	
leptin.66,81	
• No	association	with	BMI,	cholesterol,	LDL-C,	HDL-C.85	
• No	association	with	TC,	HLD-C,	LDL-C.24	
• No	association	with	anthropometric	parameters	(BMI,	weight,	fat	free	mass	(kg),	fat	mass	(kg),	
WC,	WHR,	SBP,	DBP,	RMR).23,30,47,49	
• No	association	with	anthropometric	parameters	(BMI,	weight,	fat	free	mass	(kg),	fat	mass	(kg),	
WC,	WHR,	SBP,	DBP,	RMR),	dietary	intake	(energy	(kcal/day),	carbohydrates	(g/day),	fat	(g/day),	
protein	(g/day))	and	exercise	(hrs/week)	or	adipocytokines	((IL-6),	TNF-a,	adiponectin,	resistin,	
leptin).29,46,68,71,84	
• No	associations	with	total	body	fat	mass,	BMI,	WHR,	abdominal	and	femoral	subcutaneous	fat	
mass	or	any	biochemical	markers	(n=7).13	
• No	association	with	glucose,	total	cholesterol,	LDL-C,	HDL-C,	TGs,	lipoprotein	(a),	insulin,	HOMAir,	
CRP.8	
• No	association	with	BMI,	weight,	fat	mass,	WC,	WHR,	SBP,	DBP,	glucose,	LDL-C,	TC,	insulin	or	
HOMAir.31	
• No	association	with	T2DM.74	
 
 
• No	association	with	glucose,	TC,	LDL-C,	HDL-C,	TGs,	lipoprotein	(a),	insulin,	HOMAir,	CRP.46,68	
• No	association	with	glucose,	TC,	LDL-C,	CRP,	lipoprotein	(a).29	
• No	association	with	glucose,	TC,	LDL-C,	insulin,	HOMAir,	CRP,	dietary	intake.30	
• No	association	with	SBP,	DBP,	TC,	HDL-C	or	LDL-C.9	
• No	difference	between	basal	and	post-diet	anthropometric	measurements	or	cardiovascular	risk	
factors.76	
• No	difference	in	decrease	in	BMI,	weight,	fat	mass,	fat	free	mass,	WC,	WHR,	SBP,	DBP,	glucose,	
HDL-C,	TGs	or	insulin	between	wild-	or	mutant-type	group	following	treatment	with	liraglutide.8	
• No	association	with	carbohydrate,	fat,	m-fat,	p-fat,	protein	or	fibre	intake.31	
Negative:	
• Mutant	allele	associated	with	lower	glucose.81	
• Mutant	allele	with	lower	BMI.10,11	
• Mutant	allele	with	lower	HOMAir,	TGs.10	
• Mutant	allele	associated	with	lower	weight,	BMI,	fat	mass	8,	WC,	insulin,	HOMAir	and	CRP.24	
• Mutant	allele	associated	with	lower	BMI,	SBP,	HOMAir	and	CRP	and	higher	HDL-C.	12	Lack	of	
improvement	in	cholesterol,	glucose,	insulin,	TGs,	HOMAir	and	leptin	compared	with	wild-type	
group	following	hypocaloric	diet.84	
• Mutant	allele	with	lower	TGs,	insulin	and	HOMAir	values.29	
• Mutant	allele	with	decreased	resistin,	leptin	and	IL-6	following	weight	loss.46	
• Mutant	allele	with	decreased	glucose,	insulin,	HOMAir	and	incidence	of	MetS.23	
• Mutant	allele	with	better	improvements	in	HOMAir	following	treatment	with	liraglutide.8	
• Mutant	allele	with	lower	TGs	and	higher	HDL-C.30	
• Mutant-type	group	associated	with	lower	TGs	and	higher	HDL-C,	and	lower	cholesterol	and	
saturated	fat	intake.31	
• Mutant	allele	with	decreased	dietary	cholesterol	and	saturated	fats.93	
• Mutant	allele	associated	with	lower	BMI,	WC,	HOMAir,	TG	levels	and	prevalence	of	MetS.9	
rs12720071	 CNR1	 A>G	 3813	
3	Prime	
Untranslated	
Region	(3’	
UTR)΅	
-	 -	
Positive:	
• Mutant	allele	associated	with	increased	WC	and	subscapular	skinfold	thickness.3	
Neutral:	
• No	association	with	anthropometric	(weight,	height,	BMI,	WHR,	WC)	or	biochemical	(HDL-C,	LDL-
C,	TGs,	glucose)	measurements.47,49	
• No	association	with	Anthropometric	measurements	(weight,	BMI,	WC,	total	fat	(g),	fat	(%),	
android	fat	deposit,	biochemical	measurements	(glucose,	TC,	HDL-C,	LDL-C,	TGs,	insulin,	FIRI)8	
• No	association	with	BMI,	WC,	TC,	HDL-C,	LDL-C,	TGs,	glucose,	SBP,	DBP,	MBP.88	
• No	association	with	impaired	glucose	metabolism.73	
• No	association	with	HOMAir,	insulin,	glucose.4	
• No	associations	with	BMI,	WC	or	visceral	adipose	tissue.64	
rs2023239	 CNR1	 C>T	 5489	 Intron	 -	 -	
Positive:	
• Mutant	allele	associated	with	higher	BMI.36	
Neutral	
• No	association	with	obesity.35,69	
 
 
• No	association	with	anthropometric	measurements	(weight,	BMI,	WC,	total	fat	(g),	fat	(%),	
android	fat	deposit,	biochemical	measurements	(glucose,	TC,	HDL-C,	LDL-C,	TGs,	insulin,	fasting	
insulin	resistance	index).87,91	
• No	association	with	anthropometric	measurements	(BMI,	WC,	WHR,	SBP,	DBP)	and	biochemical	
(TC,	TGs).94	
rs6454674	
	 CNR1	 G>T	 -	 -	 -	 -	
Neutral	
• No	association	with	anthropometric	measurements	(weight,	BMI,	WC,	WHR),	biochemical	
measurements	(glucose,	TC,	HDL-C,	LDL-C,	TGs,	insulin,	HOMAir).43,82,91	
rs806365	 CNR1	 C>T	 -	 -	 -	 -	
Positive:	
• Mutant	allele	with	increased	BMI	and	TGs.49	
Neutral	
• No	association	with	glucose.4	
• No	association	with	anthropometric	measurements	(BMI,	obesity,	WC,	central	obesity,	SBP,	DBP,	
hypertension)	and	metabolic	variables	(HDL-C,	LDL-C,	TGs,	HbA1c,	T2DM).16	
• No	associations	with	BMI,	waist	circumference	or	visceral	adipose	tissue.64	
• No	association	with	WC,	hip	circumference,	WHR),	insulin	responsiveness	(insulin,	glucose,	
insulin:glucose,	HOMAir),	lipids	(TC,	LDL-C,	HDL-C).49	
Negative	
• Mutant	allele	with	lower	HOMAir	and	insulin	levels.4	
rs806366	 CNR1	 T>C	 -	 -	 -	 -	
Positive:	
• Associated	with	increased	BMI	and	TGs.49	
Neutral:	
• No	association	with	HOMAir,	glucose	or	insulin	levels.4	
• No	association	with	anthropometric	measurements	(BMI,	obesity,	WC,	central	obesity,	SBP,	DBP,	
hypertension)	and	metabolic	variables	(HDL-C,	LDL-C,	TGs,	HbA1c,	T2DM).16	
• No	associations	with	BMI,	waist	circumference	or	visceral	adipose	tissue.64	
rs806368	 CNR1	 T>C	 4895	 Intron	 -	 -	
Positive:	
• Mutant	allele	associated	with	increased	WHR.47	
• Mutant	allele	associated	with	increased	TGs.49	
• Mutant	allele	associated	with	increased	BMI,	WC,	SBP	and	obesity.16	
Neutral:	
• No	association	with	weight,	height,	BMI,	WC,	HDL-C,	LDL-C,	TGs,	glucose	and	lifestyle	factors	
(n=3).47	
• No	association	with	BMI	83,	WC,	subscapular	skinfold	thickness.3	
• No	association	with	anthropometric	measurements	(weight,	BMI,	WC,	WHR),	biochemical	
measurements	(glucose,	TC,	HDL-C,	LDL-C,	TGs,	insulin,	HOMAir).43,82	
• No	association	with	HOMAir,	glucose,	insulin	levels.4	
• No	associations	with	BMI,	waist	circumference	or	visceral	adipose	tissue.64	
rs806369	 CNR1	 C>T	 -	 Intron	 -	 -	
Positive:	
• Mutant	allele	with	increased	TGs,	TC.49	
Neutral	
• No	association	with	BMI.83	
 
 
• No	association	with	BMI,	WC,	hip	circumference,	WHR,	insulin,	glucose,	insulin:glucose,	HOMAir,	
LDL-C,	HDL-C.16,49	
• No	association	with	association	with	HOMAir,	glucose	and	insulin	levels.4	
rs806370	 CNR1	 C>T	 -	 Intron	 -	 -	
Positive:	
• Mutant	allele	with	raised	HDL-C.49	
Neutral:	
• No	association	with	BMI.35,83	
• No	association	with	BMI,	WC,	hip	circumference,	WHR,	insulin,	glucose,	insulin:glucose,	HOMAir,	
TC,	LDL-C,	TGs.16,49	
rs806371	 CNR1	 G>T	 -	 Intron	 -	 -	
Neutral:	
• No	association	with	HOMAir,	glucose,	insulin	levels.4	
• No	association	with	anthropometric	measurements	(BMI,	obesity,	WC,	central	obesity,	SBP,	DBP,	
hypertension)	and	metabolic	variables	(HDL-C,	LDL-C,	TGs,	HbA1c,	T2DM)16	
• No	associations	with	BMI,	waist	circumference	or	visceral	adipose	tissue.64	
	
Negative:	
• Mutant	allele	with	lower	HDL-C	levels.79	
rs806381	 CNR1	 A>G	 10908	 Intron	 -	 -	
Positive:	
• Mutant	allele	with	higher	BMI.36	
Neutral:	
• No	association	with	anthropometric	measurements	(weight,	BMI,	WC,	WHR),	biochemical	
measurements	(glucose,	TC,	HDL-C,	LDL-C,	TGs,	insulin,	HOMAir).	13,43,82		
• No	association	with	BMI,	WC,	WHR,	SBP,	DBP,	TC,	TGs.94	
• No	association	with	anthropometric	measurements	(Weight,	BMI,	WC,	fat	(%),	android	fat	
deposit,	gynoid	fat	deposit,	SBP,	DBP)	and	biochemical	measurements	(TC,	HDL-C,	LDL-C,	TGs,	
glucose,	insulin,	FIRI).91	
rs10485179	 CNR1	 	 -	 Intron	 -	 -	 • No	association	with	obesity-related	or	glucose	metabolism	parameters.13	
rs35761398	 CNR2	 A>G	 188	 Exon	 Gln>Arg	 63	 • No	association	with	BMI,	HOMAir,	TC,	HDL-C	or	TG	levels.95	
rs3123554	 CNR2	 G>A	 -	 -	 -	 -	
Positive:	
• Mutant-type	group	had	higher	BMI,	weight,	fat	mass,	WC	TGs,	insulin	and	HOMAir	than	wild-type	
group.26	
Neutral:	
• No	difference	in	dietary	intake	between	genotypes.26	
Negative:	
• Mutant	allele	associated	with	lower	BMI,	weight	and	body	fat	in	women.	Carriers	also	lost	less	
weight	following	lifestyle	interventions.21	
rs324419	 FAAH	 A>G	 895	 Exon	 Ala>Ala	 275	
Neutral:	
• No	association	with	obesity.51	
• No	association	with	BMI,	waist	circumference	or	visceral	adipose	tissue.64	
rs324420	 FAAH	 C>A	 385	 Exon	 Pro>Thr	 129	
Positive:	
• Mutant	allele	associated	with	higher	insulin	and	HOMAir	in	patients	without	MetS.50	
• Homozygosity	for	mutant	allele	associated	with	increased	BMI.17	
• Mutant	allele	associated	with	obesity.19	
 
 
Abbreviations:	CNR1,	cannabinoid	receptor	gene	1;	CNR2,	cannabinoid	receptor	gene	2;	FAAH,	fatty	acid	amide	hydrolase;	WC,	waist	circumference;	WHR,	waist-to-hip	ratio;	SBP,	systolic	blood	pressure;	DBP,	
diastolic	blood	pressure;	RMR,	resting	metabolic	rate;	TC,	total	cholesterol;	LDL-C,	low-density	lipoprotein	cholesterol;	HDL-C,	high-density	lipoprotein	cholesterol;	TGs,	triglycerides;	HOMAIR,	homeostatic	model	
assessment	of	insulin	resistance;	FIRI,	fasting	insulin	resistance	index;	IL-6,	interleukin-6;	CRP,	C-reactive	protein;	m-fat,	monounsaturated	fat;	p-fat,	polyunsaturated	fat;	MetS,	metabolic	syndrome;	T2DM,	Type	
2	Diabetes	Mellitus.	
 
	
	
	
	
	
	
	
• Wild-type	allele	associated	with	childhood	obesity.51	
• Wild-type	genotype	associated	with	class	III	adult	obesity.20	
• Mutant	allele	associated	with	increased	HDL-C.20	
• Wild-type	allele	associated	with	higher	HDL-C	levels	in	subjects	with	MetS.53	
• Mutant	allele	associated	with	increased	TGs.32	
Neutral:	
• No	association	with	BMI.96	
• No	differences	in	cholesterol	levels	between	genotypes.	80	
• No	association	with	anthropometric	measurements	18,28	or	dietary	intake.28,44	
• No	differences	in	anthropometric,	metabolic	parameters	or	adipocytokines	between	genotypes	in	
MetS	or	non-MetS	subjects.50	
• No	association	with	BMI,	WC,	WHR,	glucose,	insulin,	C-peptide,	HOMAir,	TGs,	TC.72	
• No	association	with	binge-eating	disorder.19	
• No	association	with	child	obesity	or	T2DM.20	
• No	association	with	BMI,	waist	circumference	or	visceral	adipose	tissue.64	
• No	association	with	SBP,	DBP,	TC	or	LDL-C	levels.53	
• No	association	with	BMI,	weight,	TC,	LDL-C,	HDL-C,	TGs,	glucose,	insulin,	HOMAir,	SBP,	DBP.48	
Negative:	
• Mutant	allele	associated	with	greater	decrease	in	TGs	and	total	cholesterol	following	low	fat	
diet.85	
• Mutant	allele	associated	with	lower	TGs,	glucose,	HOMAir	and	IL-6	levels.44	
• Mutant	allele	associated	with	lower	glucose,	insulin,	HOMAir	and	visfatin	levels.28	
• Mutant	allele	associated	with	better	percentage	weight	loss	9	months	and	1	year	after	bariatric	
surgery,	but	not	after	3	months.52	
• Lower	insulin,	HOMAir	and	CRP	in	mutant-type	group.	Mutant	allele	associated	with	greater	
decreases	in	weight	and	WC	than	wild-type	following	hypocaloric	diet.	Mutant	allele	also	
associated	with	greater	decreases	in	glucose,	TC,	LDL-C,	HOMAir,	CRP	and	TGs.27	
• Mutant	allele	associated	with	lower	adiponectin	levels	and	higher	AEA	levels.42	
• Wild-type	allele	associated	with	lower	WC,	BMI,	HOMAir	and	TGs	in	subjects	with	MetS.53	
• Mutant	allele	associated	with	lower	insulin,	glucose	and	HOMAir	values.54	
• Mutant	allele	associated	with	reduced	levels	of	HDL-C.32	
 
 
Supplemental	Table	S2.	All	included	studies	and	associations	with	anthropometric	and/or	blood	measurements	of	adiposity	and	glucose	metabolism	
	
	
Study	 N	 M/F	 Population	 Endpoint	 Polymorphism	 Main	findings	 Association	
summary	
Aller	et	al.	2012	66	 71	 47/23	 NAFLD	 Body	weight,	Insulin	
resistance,	adipokines	
rs1049353	 No	differences	for:	BMI,	weight,	WC,	WHR,	glucose,	total	
cholesterol,	LDL,	HDL,	TG,	IL-6,	or	leptin.	
Mutant-type	group	had	higher	adiponectin	and	visfatin	
levels.	Wild-type	group	had	higher	HOMAir,	TNFa	and	
resistin.	
Neutral	=	11	
Positive	=	2	
Negative	=	3	
Aberle		et	al.	2008	81	 1,72
1	
688/10
33	
BMI	
>25	kg/m2 
Body	weight	parameters,	
cholesterol,	insulin	and	
glucose	
rs1049353	 At	baseline	no	differences	in	weight,	BMI,	TG,	total	
cholesterol,	HDL,	LDL.	Glucose	was	higher	in	wild-type.	
After	3	months’	diet,	mutant	allele	group	associated	with	
greater	weight	loss,	decrease	in	BMI,	and	decrease	in	LDL.		
No	differences	between	groups	in	change	in	glucose,	TGs,	
cholesterol	or	HDL.	
Neutral	=	10	
Negative	=	4	
Chmelikova	et	al.	2014	
80	
155	 Not	
reporte
d	
Chronic	
heart	failure	
Cholesterol	 rs1049353	
	
rs324420	
Homozygosity	for	mutant	allele	was	associated	with	
increased	cholesterol	levels	
No	differences	in	cholesterol	levels	between	groups	
Positive	=	1	
	
Neutral	=	1	
Col	Araz	et	al.	2012	15	 200	 	 Obese	
children	
BMI	 rs1049353	 Mutant	allele	associated	with	childhood	obesity	 Positive	=	1	
	
de	Luis	et	al.	2009	24	 66	 17/49	 Morbidly	
obese	
Anthropometric	parameters	
(n=9),	cardiovascular	risk	
factors	(n=8)	and	
adipocytokines	(n=5).	
rs1049353	 Mutant	allele	associated	with	lower	weight,	BMI,	fat	mass,	
WC,	insulin,	HOMAir	and	CRP.		
No	differences	detected	between	groups	for	other	
parameters	(n=10).	
Negative	=	7	
Neutral	=	10	
de	Luis	et	al.	2010a	68	 60	 14/46	 Diabetic	 Anthropometric	parameters	
(n=9),	cardiovascular	risk	
factors	(n=9)	dietary	intake	
(n=9)	and	adipocytokines	
(n=5).	
rs1049353	 No	association	with	anthropometric	parameters	(n=9),	
cardiovascular	risk	factors	(n=9)	dietary	intake	(n=9)	or	
adipocytokines	(n=5).	
Neutral	=	32	
de	Luis	et	al.	2011a	84	 249	 56/193	 BMI>30	kg/
m2	
Anthropometric	parameters	
(n=10),	cardiovascular	risk	
factors	(n=8)	and	
adipocytokines	(n=5).	
rs1049353	 No	association	with	basal	or	post-treatment	
anthropometric	or	biochemical	variables	in	either	wild-	or	
mutant-type	group	(n=46)	
No	difference	in	effect	of	either	diet	on	anthropometric	
variables	(n=20)	
No	difference	in	effect	of	either	diet	on	glucose,	TC,	
insulin	and	HOMAir	values	between	mutant-	or	wild-type	
group.	
No	improvement	of	mutant-type	group	in	cholesterol,	
glucose,	insulin,	TG,	HOMAir	and	leptin	values	compared	
with	wild-type	group	following	either	diet.	
Neutral	=	74	
Negative	=	12	
de	Luis	et	al.	2011b	29	 290	 0/290	 BMI>30	kg/
m2	
Anthropometric	variables	
(n=9),	cardiovascular	risk	
factors	(n=9),	dietary	intake	
rs1049353	 No	association	with	anthropometric	variables	(n=9),	
dietary	intake	(n=9)	or	adipocytokines	(n=5)	
Mutant	allele	associated	with	better	cardiovascular	profile	
(lower	TGs,	insulin	and	HOMAir,	higher	HDL)	
Neutral	=	28	
Positive	=	1	
Negative	=	3	
 
 
(n=9)	and	adipocytokines	
(n=5)	
No	association	with	glucose,	TC,	LDL-C,	CRP,	lipoprotein	
(a).		
de	Luis	et	al.	2011c	46	 94	 24/70	 BMI>30	kg/
m2	
Anthropometric	variables	
(n=9),	cardiovascular	risk	
factors	(n=9),	dietary	intake	
(n=5)	and	adipocytokines	
(n=5)	
rs1049353	 No	difference	in	basal	and	post-treatment	anthropometric	
measurements	(n=18),	cardiovascular	risk	factors	(n=18),	
dietary	intake	(n=5)	or	cytokines	(n=5)	between	the	two	
genotypes	
Mutant	allele	associated	with	decreased	resistin,	leptin	
and	IL-6	following	weight	loss	
Neutral	=	46	
Negative	=	3	
de	Luis	et	al.	2011d	23	 917	 Not	
reporte
d	
BMI>30	kg/
m2	
Anthropometric	variables	
(n=7),	biochemical	variables	
(n=7)	and	adipocytokines	
(n=3)		
rs1049353	 Mutant	allele	associated	with	lower	glucose,	insulin	and	
HOMAir	values	and	decreased	prevalence	of	metabolic	
syndrome	
Negative	=	4	
Neutral	=	28	
de	Luis	et	al.	2013	76	 258	 64/194	 BMI>30	kg/
m2	subject	
to	one	of	
two	
hypocaloric	
diets	
Anthropometric	variables	
(n=7),	cardiovascular	risk	
factors	(n=8)	and	
adipocytokines	(n=5)	
rs1049353	 No	difference	between	basal	and	post-treatment	
anthropometric	measurements	(n=14),	cardiovascular	risk	
factors	(n=16)	or	adipocytokines	(n=8)	
Mutant	allele	associated	with	lack	of	decrease	in	leptin	
following	both	diets.		
Neutral	=	38	
Positive	=	2	
de	Luis	et	al.	2014	8	 86	 44/42	 BMI>30	kg/
m2	with	
T2DM,	given	
liraglutide	
Anthropometric	variables	
(n=8),	cardiovascular	risk	
factors	(n=8)	
rs1049353	 BMI,	weight,	fat	mass	and	WC	higher	in	wild-type	group	
pre-	and	post-treatment.	
No	difference	in	biochemical	parameters	(n=8)	pre-
treatment	
No	difference	in	decrease	in	BMI,	weight,	fat	mass,	fat	
free	mass,	WC,	WHR,	SBP,	DBP,	glucose,	HDL-C,	TGs	or	
insulin	between	wild-	or	mutant-type	group	following	
treatment	
Wild-type	allele	associated	with	better	improvements	in	
LDL-C	and	TC	
Mutant	allele	associated	with	better	improvements	in	
HOMAir	levels	following	treatment.	
Neutral	=	17	
Positive	=	2	
Negative	=	5	
de	Luis	et	al.	2015a	71	 190	 57/133	 European	 BMI,	weight,	fat	mass,	WC,	
WHR,	SBP,	DBP	
Glucose.	TC.	LDL-C,	HDL-C,	
TGs,	insulin,	HOMAir,	CRP.		
Adiponectin,	resistin,	leptin.	
Measured	at	baseline,	3	
months	and	9	months	
following	diet.	
rs1049353	 No	association	with	any	measured	parameters.	 Neutral	=	54	
de	Luis	et	al.	2015b	30	 341	 120/22
1	
BMI>30	kg/
m2	
Anthropometric	variables	
(n=8),	cardiovascular	risk	
factors	(n=8)	and	dietary	
intake	(n=9)	
rs1049353	 No	associations	with	anthropometric	variables	(n=8)	
Mutant-type	group	associated	with	lower	TGs	and	higher	
HDL-C	
No	associations	with	glucose,	TC,	LDL-C,		insulin,	HOMAir,	
CRP	or	dietary	intake	measurements	(n=9)	
Neutral	=	24	
Positive	=	1	
Negative	=	1	
 
 
de	Luis	et	al.	2015c	31	 896	 0/896	 Female,	
BMI>30	kg/
m2	
Anthropometric	variables	
(n=7),	cardiovascular	risk	
factors	(n=7)	
rs1049353	 No	association	with	BMI,	weight,	fat	mass,	WC,	WHR,	SBP,	
DBP,	glucose,	LDL-C,	TC,	insulin	or	HOMAir.	
No	association	with	energy,	carbohydrate,	fat,	
monounsaturated	fat,	polyunsaturated	fat,	protein	or	
fibre	intake.	
Mutant-type	group	associated	with	lower	TGs	and	higher	
HDL-C,	and	lower	cholesterol	and	saturated	fat	intake.	
Neutral	=	19	
Positive	=	1	
Negative	=	3	
Dinu	et	al.	2011	75	 305	 -	 Romanian,	
35-75	years		
Adiponectin	 rs1049353	 Mutant	allele	associated	with	higher	adiponectin	levels	 Positive	=	1	
Gazzerro	et	al.	2007	11	 419	 237/18
2	
Italian,	>65	
years	
BMI	 rs1049353	 Mutant	allele	associated	with	lower	BMI	 Negative	=	1	
Hu	et	al.	2010	9	 518	 209/17
3	
Chinese	Han	 BMI,	WC,	SBP,	DBP,	HOMAir,	
TGs,	TC,	HDL-C,	LDL-C	
rs1049353	 Mutant	allele	associated	with	lower	BMI,	WC,	HOMAir,	TG	
levels	and	prevalence	of	MetS.	
No	association	with	SBP,	DBP,	TC,	HDL-C	or	LDL-C	
Neutral	=	5	
Positive	=	1	
Negative	=	4	
Muller	et	al.	2007	35	 2,59
5	
768/18
27	
BMI>30	kg/
m2	
BMI	 rs1049353	
rs1535255	
rs2023239	
rs6454676	
rs754387	
rs806370	
rs806379	
rs9353527	
No	association	with	obesity	for	any	polymorphism	studied	 Neutral	=	8	
Peeters		et	al.	2007	14	 1,06
4	
455/56
8	
BMI>30	kg/
m2	
WC,	WHR,	fat	mass	(kg),	fat	
mass	(%)	
rs1049353	 Homozygosity	for	mutant	allele	associated	with	increased	
WHR	and	WC	in	obese	men	only.		
No	other	associations	
Neutral	=	6	
Positive	=	2	
Aberle		et	al.	2007	85	 451	 264/18
7	
BMI>30	kg/
m2	
BMI,	TGs,	cholesterol,	LDL-C,	
HDL-C,	VLDL-C,	lipoprotein	
(a),	glucose	
rs1049353	
rs324420	
No	associations	with	rs1049353	
Mutant	allele	associated	with	greater	decrease	in	TGs	and	
total	cholesterol	following	low	fat	diet	
Neutral	=	14	
Negative	=	2	
Frost	et	al.	2010	13	 783	 783/0	 Danish,	20-
29	years,	
male	
Body	weight	parameters	
(n=3)	
MRI	measurements	(n=4),	
biochemical	markers	(n=7)	
rs1049353	
	
	
	
rs10485179	
rs806381	
Wild-type	allele	associated	with	visceral	and	
intermuscular	fat	mass,	higher	TGs.	No	associations	with	
total	body	fat	mass,	BMI,	WHR,	abdominal	and	femoral	
subcutaneous	fat	mass	or	any	biochemical	markers	(n=7)	
No	association	with	rs10485179	or	rs806381	for	any	
endpoint	(n=28)	
Neutral	=	41	
Positive	=	3	
Jaeger		et	al.	2008	47	 756	 309/44
7	
Caucasian	 Anthropometric	(weight,	
height,	BMI,	WHR,	WC),	
biochemical	(HDL-C,	LDL-C,	
TGs,	glucose)	and	lifestyle	
factors	(n=3)	
rs1049353	
rs12720071	
rs806368	
No	associations	
No	associations	
rs806368	associated	with	increased	WHR.	No	other	
associations.	
Neutral	=	35	
Positive	=	1	
Reinhard	et	al.	2008	97	 1,96
8	
1,072/8
96	
MI	patients	 Obesity,	arterial	
hypertension,	
hypercholesterolaemia,	
T2DM.	
rs4649119	
rs3003328	
rs1130321	
rs2229586	
rs2229579	
rs3003328	and	rs2229586	associated	with	
hypercholesterolaemia.	No	other	associations	with	any	
SNP	and	endpoint.	
Neutral	=	50	
Positive	=	2	
 
 
rs4649124	
rs2501431	
rs16828926	
rs2501390	
rs2501399	
rs9424339	
rs7530595	
rs17338135	
Baye	et	al.	2008	49	 1,56
0	
Not	
reporte
d	
Obese	and	
non-obese	
subjects	
Anthropometric	parameters	
(BMI,	WC,	hip	circumference,	
WHR),	insulin	responsiveness	
(insulin,	glucose,	
insulin:glucose,	HOMAir),	
lipids	(TC,	LDL-C,	HDL-C,	TGs)	
rs1049353	
rs12730071	
rs806366		
rs806368		
rs806369	
rs806370	
rs806366	associated	with	BMI	and	TGs	
rs806370	associated	with	HDL-C	
rs806369	associated	with	TGs,	TC	
rs806368	associated	with	TGs	
No	associations	with	obesity	parameters,	insulin	
responsiveness	or	lipid	levels	for	rs1049353	or	
rs12720071	
Haplotype	H4	associated	with	higher	BMI,	insulin	and	
lipids.		
Neutral	=	56	
Positive	=	9	
	
Lenarcik-Kabza	et	al.	
2014	82	
130	 0/130	 Subjects	
with	PCOS	
Anthropometric	
measurements	(weight,	BMI,	
WC,	WHR),	biochemical	
measurements	(glucose,	TC,	
HDL-C,	LDL-C,	TGs,	insulin,	
HOMAir)		
rs1049353	
rs10485170	
rs2023239	
rs6454674	
rs806381	
rs806368	
Homozygosity	for	rs2023239	wild-type	allele	associated	
with	higher	TC	and	LDL-cholesterol	in	women	with	PCOS.	
No	other	associations.	
No	association	with	anthropometric	or	biochemical	
measurements	for	any	other	polymorphism	in	study.	
Neutral	=	64	
Positive	=	2	
Milewicz	et	al.	2010	43	 348	 0/348	 Postmenopa
usal	women	
Anthropometric	
measurements	(weight,	BMI,	
WC,	total	fat	(g),	fat	(%),	
android	fat	deposit,	
biochemical	measurements	
(glucose,	TC,	HDL-C,	LDL-C,	
TGs,	insulin,	fasting	insulin	
resistance	index)	
rs1049353	
rs10485170	
rs12720071	
rs2023239	
rs6454674	
rs806368	
rs806381	
rs1049353	associated	with	higher	android	fat	deposit	and	
percentage	of	android	fat.	No	other	associations.	
No	associations	for	any	other	polymorphism.	
Neutral	=	89	
Positive	=	2	
Bordicchia	et	al.	2010	
88	
280	 Not	
reporte
d	
Obese	
hypertensive	
BMI,	WC,	TC,	HDL-C,	LDL-C,	
TGs,	glucose,	SBP,	DBP,	MBP,	
MetS	
rs12720071	 Mutant	allele	associated	with	lower	prevalence	of	
metabolic	syndrome.	
No	other	associations	observed.		
Neutral	=	10	
Negative	=	1	
Dinu	et	al.	2010	73	 191	 Not	
reporte
d	
Romanian,	
35-75	years	
Glucose	 rs12720071	 No	association	with	impaired	glucose	metabolism	 Neutral	=	1	
Russo	et	al.	2007	3	 1,21
3	
1,213/0	 White	adult	
male	
BMI,	WC,	subscapular	
skinfold	thickness	
rs12720071	
	
	
rs806368	
Mutant	allele	associated	with	increased	WC	and	
subscapular	skinfold	thickness.	
	
No	association.	
Neutral	=	4	
Positive	=	2	
 
 
Schleinitz	et	al.	2010	83	 2,77
4	
Not	
reporte
d	
Two	German	
cohorts	
BMI,	WHR,	fat,	glucose,	
insulin,	leptin,	adiponectin	
rs1049353	
rs12720071	
rs806368	
rs806369	
rs806370	
No	associations	observed.	 Neutral	=	35	
Wangensteen	et	al.	
2010	22	
5,01
1	
1,235/3
,776	
Norwegian	
Caucasian	
BMI	 CB1:	
rs1049353	
rs12720071	
rs806368	
NAPE-PLD:	
rs13232194	
rs17605251	
rs11487077	
rs12540583	
rs6465903	
Haplotype	I	(combination	of	alleles	of	rs13232194,	
rs17605251,	rs11487077,	rs12540583	and	6465903)	
protective	against	severe	obesity	
-	
Benzinou	et	al.	2008	36	 1,93
2	
Not	
reporte
d	
Caucasian	 	 rs2023239	
rs806381	
Mutant	alleles	of	both	polymorphisms	associated	with	
higher	BMI		
	
Positive	=	2	
Zhuang	et	al.	2012	94	 2,81
2	
0/2,812	 Chinese	
female,	50-
64	years	
Anthropometric	
measurements	(BMI,	WC,	
WHR,	SBP,	DBP)	and	
biochemical	(TC,	TGs)	
rs2023239	
rs806381	
No	association	between	rs2023239	and	any	
anthropometric	or	biochemical	measurements	
rs806381	mutant	allele	associated	with	increased	TGs.	No	
association	with	this	allele	and	any	anthropometric	
measurements.	
Neutral	=	13	
Positive	=	1	
Laczmanski	et	al.	2011	
91	
348	 0/348	 Polish	post-
menopausal	
women	
Anthropometric	
measurements	(Weight,	BMI,	
WC,	fat	(%),	android	fat	
deposit,	gynoid	fat	deposit,	
SBP,	DBP)	and	biochemical	
measurements	(TC,	HDL-C,	
LDL-C,	TGs,	glucose,	insulin,	
FIRI).	
rs10485170	
rs2023239	
rs6454674		
rs806381	
No	associations	with	any	polymorphism.	 Neutral	=	60	
de	Luis	et	al.	2010b	44	 279	 0/279	 Obese	
female	
Anthropometric	variables	
(n=9),	cardiovascular	(n=9)	
and	dietary	intake	(n=9)	
rs324420	 No	association	with	anthropometric	measurements	or	
dietary	intake.	
Mutant	allele	associated	with	lower	TGs,	glucose,	HOMAir	
and	IL-6	levels	
Neutral	=	23	
Negative	=	4	
de	Luis	et	al.	2010c	28	 143	 0/143	 Obese	
female	
Anthropometric	variables	
(n=9),	metabolic	variables	
(n=9),	dietary	intake	(n=9)	
rs324420	 No	association	with	anthropometric	measurements.	
Mutant	allele	associated	with	lower	glucose,	insulin,	
HOMAir	and	visfatin	levels.		
No	association	with	dietary	intake.	
Neutral	=	23	
Negative	=	4	
de	Luis	et	al.	2010d	52	 67	 16/51	 BMI	>40	
kg/m2,	
bariatric	
surgery	
patients 
Anthropometric	variables	
(n=6),	metabolic	variables	
(n=5)	
rs324420	 No	differences	between	genotypes	in	baseline	
anthropometric	measurements.		
Mutant	allele	associated	with	better	percentage	weight	
loss	9	months	and	1	year	after	bariatric	surgery,	but	not	
after	3	months.		
Neutral	=	32	
Negative	=	12	
 
 
	 No	association	with	metabolic	variables	at	baseline,	3	
months,	9	months	or	12	months.	
	
de	Luis	et	al.	2011e	27	 122	 33/89	 BMI	>30	
kg/m2	
Anthropometric	variables	
(n=9),	cardiovascular	(n=9)	
and	dietary	intake	(n=5)	
rs324420	 Lower	insulin,	HOMAir	and	CRP	in	mutant-type	group	at	
baseline.		
Mutant	allele	associated	with	greater	decreases	in	weight	
and	WC	than	wild-type	following	hypocaloric	diet.	
Mutant	allele	also	associated	with	greater	decreases	in	
glucose,	TC,	LDL-C,	HOMAir,	CRP	and	TGs.	
No	association	with	dietary	intake	measurements	at	
baseline	or	3	months.		
	
Neutral	=	35	
Negative	=	11	
de	Luis	et	al.	2012	50	 799	 248/55
1	
BMI	>30	
kg/m2	
Anthropometric	variables	
(n=7),	metabolic	variables	
(n=7)	and	adipocytokines	
(n=5)	
rs324420	 Mutant	allele	associated	with	higher	insulin	and	HOMAir	
in	patients	without	MetS.	No	differences	in	
anthropometric,	metabolic	parameters	or	adipocytokines	
between	genotypes	in	MetS	or	non-MetS	subjects.		
Neutral	=	36	
Positive	=	2	
de	Luis	D	et	al.	2017	26	 1,02
7	
280/74
7	
BMI	>30	
kg/m2	
Anthropometric	variables	
(n=5),	cardiovascular	(n=10)	
and	dietary	intake	(n=9)	
rs3123554	 Mutant-type	group	had	higher	BMI,	weight,	fat	mass,	WC	
TGs,	insulin	and	HOMAir	than	wild-type	group.	
No	difference	in	dietary	intake	between	genotypes.	
		
Neutral	=	17	
Positive	=	7	
Ketterer	et	al.	2014	21	 2,00
6	
	 Subjects	at	
risk	of	T2DM	
BMI,	weight,	WHR,	total	body	
fat	(%)	
rs3123554	
rs2229579	
rs2501392	
rs9424398	
rs4625225	
	
rs3123554	mutant	allele	associated	with	lower	BMI,	
weight	and	body	fat	in	women.	Carriers	also	lost	less	
weight	following	lifestyle	interventions	
No	associations	found	with	any	other	polymorphism.	
Neutral	=	17	
Negative	=	3	
Jensen	et	al.	2007	72	 5,73
8	
2,887/2
,851	
Obesity	 BMI,	WC,	WHR	
Glucose,	insulin,	C-peptide,	
HOMAir,	TGs,	TC	
rs324420	 No	association	with	any	measured	parameters.	 Neutral	=	9	
Martins	et	al.	2015	42	 200	 100/10
0	
Normal/obe
se	
Anthropometric	
measurements	(n=6),	
metabolic	variables	(n=7),	
adipocytokines/endocannabi
noids	(n=7)	
rs324420	 Mutant	allele	associated	with	lower	adiponectin	levels	
and	higher	AEA	levels.	No	other	associations	observed.	
Neutral	=	18	
Negative	=	2	
Monteleone	et	al.	
2008	19	
189	 0/189	 Subjects	
with	binge-
eating	
disorder	
Obesity,	binge-eating	
disorder	
rs324420	 Mutant-allele	associated	with	overweight	and	obesity,	but	
not	binge-eating	disorder	
Neutral	=	1	
Positive	=	2	
Muller	et	al.	2010	51	 10,4
98	
5,072/5
,426	
Obese	
children	and	
adolescents,	
siblings	and	
parents.	
Obesity	(childhood,	adult)	 rs324419	
rs324420	
rs2295632	
rs873978	
rs324420	wild-type	allele	associated	with	childhood	
obesity	but	not	adult	obesity.	
Neutral	=	7	
Positive	=	1	
 
 
Sipe		et	al.	2005	17	 2,66
7	
Not	
reporte
d	
Caucasian,	
black	and	
Asian	
subjects	
BMI	 rs324420	 Homozygosity	for	mutant	allele	associated	with	increased	
BMI.	
Positive	=	1	
de	Miguel-Yanes		et	al.	
2011	25	
2,41
1	
1,157/1
,254	
Caucasian	 HOMAir,	insulin,	glucose.	 rs10485171	
rs806365	
rs7766029	
rs806366	
rs806368	
rs12720071	
rs1049353	
rs806369	
rs806371	
rs806374	
rs806375	
rs806376	
rs806380	
rs7752758	
rs12528858	
rs12205430	
rs6454673	
rs6914429	
	
rs806365	wild-type	allele	associated	with	higher	HOMAir,	
but	not	glucose	in	initial	testing.		
Those	in	bold	underwent	meta-analysis	for	association	
with	HOMAir,	glucose	and	insulin	levels,	with	rs806365	
being	associated	with	HOMAir	and	insulin	levels.		
Neutral	=	42	
Negative	=	4	
Mutombo		et	al.	2011	
16	
1,45
2	
678/77
4	
Japanese,	
25-74	years	
Anthropometric	
measurements	(BMI,	obesity,	
WC,	central	obesity,	SBP,	
DBP,	hypertension)	and	
metabolic	variables	(HDL-C,	
LDL-C,	TGs,	HbA1c,	T2DM)	
rs806368	
rs806378	
rs806377	
rs806376	
rs806375	
rs12720072	
rs12195101	
rs806374	
rs806371	
rs806370	
rs806369	
rs1049353	
rs16880260	
rs4707436	
rs12720071	
rs45516291	
rs7738931	
rs12189668	
rs806366	
rs7766029	
rs16880218	
rs806365	
rs806368	mutant	allele	associated	with	increased	BMI,	
WC,	SBP	and	obesity.	No	other	associations.		
Neutral	=	272	
Positive	=	4	
 
 
rs35951010 
Lieb	et	al.	2009	64	 2,41
5	
1,143/1
,275	
Caucasian	 BMI,	WC,	visceral	adipose	
tissue	
rs10485171	
rs806365	
rs7766029	
rs806366	
rs806368	
rs12720071	
rs1049353	
rs806369	
rs806371	
rs806374	
rs806375	
rs806376	
rs806380	
rs7752758	
rs12528858	
rs12205430	
rs6454673	
rs6914429	
rs12073998	
rs6703669	
rs3766246	
rs324420	
rs324419	
rs2295633	
rs12029329	
rs324425	
rs7520850	
No	associations	with	BMI,	waist	circumference	or	visceral	
adipose	tissue	for	any	polymorphism.	
Neutral	=	81	
Caruso	et	al.	2012	93	
	
118	 60/58	 Elderly	(65-
75	years)	
BMI,	TC,	HDL-C,	TGs,	glucose	
and	dietary	variable	(n=14)	
rs1049354	
	
Mutant	allele	associated	with	decreased	dietary	
cholesterol	and	saturated	fats.	
Neutral	=	17	
Negative	=	2	
Buraczynska	et	al.	
2014	74	
667	 330/33
7	
Polish,	
T2DM	
subjects	
T2DM,	HbA1c,	BMI.	 rs1049354	 No	association	with	T2DM.	
Mutant	allele	associated	with	increased	BMI	in	T2DM	
subjects	
Neutral	=	1	
Positive	=	2	
Durand	et	al.	2008	20	 5,10
9	
2,274/2
,835	
French	
Caucasian	
Child	obesity,	adult	obesity,	
T2DM,	BMI,	glucose,	insulin,	
WC,	HDL-C,	TC,	TGs.	
rs324420	 Wild-type	genotype	associated	with	class	III	adult	obesity,	
but	not	child	obesity	or	T2DM.		
Mutant	allele	associated	with	increased	HDL-C	
Neutral	=	8	
Positive	=	1	
Negative	=	1	
Liu	et	al.	2011	10	
	
242	 -	 	 	 rs1049353	
	
In	patients	with	coronary	artery	disease,	the	mutant	allele	
was	associated	with	lower	BMI,	HOMAir	and	TGs,	and	
higher	HDL-C	
	
Zeng	et	al.	2011	53	
		
191	 109/82	 MetS	
subjects,	
healthy	
controls	
BMI,	WC,	SBP,	DBP,	HOMAir,	
TGs,	TC,	HDL-C,	LDL-C	
rs324420	
	
Wild-type	allele	associated	with	lower	WC,	BMI,	HOMAir	
and	TGs,	and	higher	HDL-C	levels	in	subjects	with	MetS.	
No	association	with	SBP,	DBP,	TC	or	LDL-C	levels.	
Neutral	=	4	
Positive	=	4	
Negative	=	1	
 
 
Feng	et	al.	2013	79	 1,00
6	
497/50
9	
European	 HDL-C	 rs806371	 Mutant	allele	associated	with	lower	HDL-C	levels	 Negative	=	1	
Tiwari	et	al.	2010	92	 183	 124/59	 Schizophreni
a/schizoaffe
ctive	
disorder	
Antipsychotic-induced	weight	
gain	
rs806378	
rs806380	
rs2180619	
rs9450902	
rs10485170	
rs806378	mutant	allele	associated	with	antipsychotic-
induced	weight	gain	
Neutral	=	4	
Positive	=	1	
Vazquez-Roque	et	al.	
2011	98	
	
62	 19/43	 Overweight/
obese	
Gastric	motor	function	
variables	(n=6)	
rs324420	
rs806378	
rs806378	mutant	allele	associated	with	increased	gastric	
volume.		
No	associations	between	rs324420	and	gastric	motor	
function.	
Neutral	=	11	
Positive	=	1	
	
Wang	et	al.	2012	12	
	
544	 263/28
1	
T2DM	
subjects	
BMI,	SBP,	DBP,	glucose,	
HOMAir,	TGs,	TC,	HDL-C,	LDL-
C,	HbA1c,	CRP	
rs1049354	
	
Mutant	allele	associated	with	lower	BMI,	SBP,	HOMAir	
and	CRP	and	higher	HDL-C.	No	other	associations	seen.	
Neutral	=	6	
Negative	=	4	
Positive	=	1	
Grolmusz	et	al.	2013	54	
	
130	 0/130	 Women	with	
PCOS,	
healthy	
controls	
BMI,	WC,	glucose,	insulin,	
HOMAir	
rs324420	 Mutant	allele	associated	with	lower	insulin,	glucose	and	
HOMAir	values	in	healthy	controls,	but	not	PCOS	subjects.	
Neutral	=	7	
Negative	=	3	
Zhang	et	al.	2009	32	
	
1,64
4	
Not	
reporte
d	
Subjects	of	
Northern	
European	
ancestry	
BMI,	HDL-C,	TGs,	insulin	
sensitivity	
rs324420	 Mutant	allele	associated	with	increased	TGs	and	reduced	
levels	of	HDL-C	
Neutral	=	2	
Positive	=	1	
Negative	=	1	
Suárez-Pinilla	et	al.	
2015	69	
	
65	 44/21	 Subjects	
with	first	
episode	
psychosis	
BMI	at	baseline	and	3	years	
follow-up	
rs1049353	
rs2023239	
rs1535255	
No	association	between	any	polymorphism	and	BMI.	
	
Neutral	=	6	
Bellini	et	al.	2015	95	
	
240	 0/240	 Female,	BMI	
>30	kg/m2	
BMI,	HOMAir,	TC,	TGs,	HDL-C	 rs35761398	
	
No	association	with	BMI,	HOMAir,	TC,	HDL-C	or	
triglyceride	levels	
Neutral	=	5	
Knoll	et	al.	2012	48	
	
453	 Not	
reporte
d	
Overweight/
obese	
children	and	
adults	
BMI,	weight,	TC,	LDL-C,	HDL-
C,	TGs,	glucose,	insulin,	
HOMAir,	SBP,	DBP.	
rs324420	
	
No	association	with	any	measured	outcome	 Neutral	=	11	
Papazoglou	et	al.	2008	
96	
303	 153/15
0	
Obesity,	
obesity	and	
MetS	
BMI	 rs324420	 No	association	with	BMI	 	
Harismendy	et	al.	
2010	99	
	
289	 -	 BMI	>40	
kg/m2	
BMI	 rs16830415	
rs9832418	
rs547801	
rs520154	
rs60963555	
rs684358	
rs9852837	
rs9829319	
rs9829320	
No	association	with	BMI	
No	association	with	BMI	
No	association	with	BMI	
Associated	with	high	BMI	
Associated	with	high	BMI	
Associated	with	high	BMI	
Associated	with	high	BMI	
Associated	with	high	BMI	
No	association	with	BMI	
Neutral	=	7	
Positive	=	8	
 
 
rs9829321	
rs9877819	
rs28753886	
rs35948688	
rs874546	
rs2011138	
No	association	with	BMI	
No	association	with	BMI	
No	association	with	BMI	
Associated	with	high	BMI	
Associated	with	high	BMI	
Associated	with	high	BMI	
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